Online inquiry

IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10361MR)

This product GTTS-WQ10361MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10361MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11914MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ1708MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ7969MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ203MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ14086MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ1598MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ15057MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ926MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW